Thanks, third Brian. Good everyone, earnings quarter call. to our afternoon, and welcome XXXX
today our Financial Here is with Sung, Chief Derrick Officer. me
quarter course the sales. record our demonstration third navigated be delta business, pandemic. from of consecutive date another generated the revenue in worldwide third the we results The our of and quarter, sales Despite unexpected to in we of of another proved XXXX headwinds highest and the yet quarter variant, as million resilience unpredictable to of $XX.X the significant
sequentially of over strong delta were were COVID of in Midwest. our across amongst highlighting with centers, we driven million saw the the the hospitals by geographically Our procedure We from Zephyr procedure treating as quarter US, evidence still demand new saw impact an we physicians the we In South, new COVID such receding in second procedures with the demand valve strong where performance This Outside States, XX the were by constraints. affected magnitude delays COVID experienced reopened treatment. continued centers life-changing mixed, of cases of Northeast $X.X clear COVID, of hard significant for hospitals results least in treatment of the volumes that US, added hospital surpass and were growing deceleration bring regions sales procedures grow expect the areas capacity regions underlying despite hit target such across the Though US sales Europe new a quarter. the Zephyr US in Zephyr US now and prolonged as sales to third in our strong to and a accelerating to XXX strong in valve revenue. States experiencing United to acceleration variant, treating patients by our the were their total less to and similar treating In procedure. to United able set we desire have for a easily high XXX centers the the establishing of of quarter, by impacted less our due Zephyr year-end. indication as patients. the at contrasted valve by for We
StratX continued directly saw of calls into engagement with in procedure geographies our patient our all the and also volumes patient and We media centers our treatment both website US channels. social patient in interest across increase sustained and momentum via an
also their terms XXX,XXX cultivated over of Zephyr In of enabling a has patients community treatment awareness of media to transformed to how that, lives. and demand say We've valves worldwide. social valves I'm experience followers of Zephyr patients share into milestones, this growing and over XX,XXX pleased have stories worldwide translated the of
commercial Turning plans. expansion to our
completed territories now year force across XX international have US with our planned active territories. total the We active sales expansion the sales and for XX
our and during provide these We on continue quarterly expand expect team plans to year greater throughout our commercial to next call. we'll next detail
major multiple of Cross front, our Blue lives reimbursement Anthem across states. with wins string Blue the XX decision million Shield, Cross policy covering Blue plans a Blue coverage Shield from largest extended we positive On of the family
efforts lives. wins for additional patients of We and the to waiting technology clinical prior Cross Shield reduce and validate These also acceptance XX the which emphysema. procedure Blue treatment. time authorization Shield for Jersey, to with receive those Blue Blue Blue our our Cross Horizon support updated cover valve in the of New continue secured of wins UK, Spain outside policy million Michigan together an already China, penetrate and France the place Furthermore, documents our were in these with to Denmark our with national recommendations markets treatment Zephyr US, further. to together severe These Germany patients will in recommend guidance and
our eligible patients, longer-term due our initiatives are who on remain are solution to excited remain international with convert has severe collateral to of has about picked track. in trial not the as impact We patients clinical COVID patients AeriSeal, on waned. AeriSeal the ventilation Enrollment ventilation. Zephyr growth to valves up for eligible of emphysema collateral European Zephyr treat that sites the multicenter studying valve, into currently trial we developing our Finally use
the we introduce valves both expect to our remain authorities of lingering approval of Japan, to and long-term prospects All told, efforts our Zephyr addition, staffing end challenges. year. the submit both and the business, increasing this application of indications Japanese continues to for we progress of our confident to In despite and the regulatory into impact before hospital near in COVID
maintain years I conviction in Zephyr and more turn call ahead. of our demand believe we that, third we As provide sustained valves the look review growth the our are With to building we in deliver quarter for results. detailed to strong underlying will necessary the a the ahead, over foundation to now Derrick